Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Six‐month real‐world amyloid PET outcomes after lecanemab: Greater amyloid reduction at the MCI stage than in dementia
Saved in:
| Published in: | Alzheimer's & Dementia: Translational Research & Clinical Interventions |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Six‐month real‐world amyloid PET outcomes after lecanemab: Greater amyloid reduction at the MCI stage than in dementia
- Relationships between longitudinal retinal amyloid imaging and amyloid PET in the A4 Trial
- Lecanemab and amyloid‐related imaging abnormalities: Real‐world data from a single center experience
- Identification of patients receiving amyloid‐targeting therapies in observational studies using amyloid PET trajectories: Insights from LEADS
- Regional amyloid PET asymmetry and long‐term clinical trajectory in mild cognitive impairment
- Clinical and MRI features associated with amyloid positivity in secondary screening for anti–amyloid‐β therapy
- Anti‐amyloid nanobody‐Fc fusion protein drives potent amyloid clearance through microglial recruitment